Comparison of Corticotrophin and Prednisolone in
Summary In a controlled trial of the effects of intramuscular corticotrophin and oral prednisolone in the treatment of acute Bell's palsy 186 successive patients with idiopathic facial palsy were grouped for age and duration of palsy. They were then allocated at random to either corticotrophin or prednisolone therapy in pairs. The results were:
(1) 94 received corticotrophin and 32 developed some degree of denervation and 92 received prednisolone and 13 developed some degree of denervation (P <0 005); (2) six of the corticotrophin group became severely denervated (less than 50% recovery) compared with none of the prednisolone group (P <0 02); (3) the best results were obtained in the younger patients (less than 45 years old) treated on the first or second day of palsy; and (4) side effects were minimal.
It is concluded that oral prednisolone is the treatment of choice for idiopathic facial (Bell's) palsy.
Introduction
Evidence has previously been presented that daily injections of corticotrophin significantly reduce the overall incidence both of denervation and of severe degrees of denervation carrying permanent disability in Bell's palsy (Taverner et al., 1966) . It has sometimes been claimed that corticotrophin is more effective than oral steroid therapy in the treatment of inflammatory neurological disorders (Jonsson et al., 1951; Ross et al., 1958; Miller et al., 1961) but firm supporting evidence is lacking. After a suggestion from Professor H. Miller (personal communication, 1966) it was decided to compare these two agents in the treatment of Bell's palsy. The results of this trial are now reported.
Design of Trial
Only patients who were having their first attack of facial palsy and were aged 21 to 70 years inclusive were admitted. Those with clinical or laboratory evidence of herpes zoster were excluded. Also excluded were those with a history of peptic ulceration; with evidence of active infection, especially of the middle ear; with evidence of more widespread neurological disease; with known hypertension; with diabetes mellitus; or in the first six months of pregnancy. Patients with an incomplete facial palsy, plus an anodal galvanic threshold of less than 10 ,A or less than 5 t±A difference between each side of the tongue (Peiris and Miles, 1965) , and with no hyperacusis or subjective taste disturbance were also excluded. Patients were seen weekly for one month, then monthly for three months, and then three-monthly up to nine months unless completely recovered. The degree of movement of the forehead and corner of the mouth and of eyelid closure was assessed as a percentage of the sound side, and the presence of any associated movements on eye closure or retraction of the mouth was carefully noted. Any unilateral associated movement at all, however slight, was taken as evidence of denervation and therefore indicated failure of that particular treatment. All the patients were photographed at their last attendance. Four half-plate black-and-white prints of full face-at rest, eyes tightly closed, showing the teeth, and raising the eyebrowswere prepared. These photographs were used by an independent observer to check the results. When the second assessment differed from the first by more than 5% the patient was recalled for review by the second observer. There were only two differences of opinion in the complete recovery group-on review one case was confirmed as complete recovery and one was judged as having denervated slightly. Nineteen of the denervated group were reviewed and in each case the verdict of the independent observer was adopted. None of these was classified as complete recovery. One patient died and one was in America-in these the original category was adopted.
Results
One hundred and eighty-six patients completed the trial and 293 were rejected for the reasons given in Table I Analysis of the results in relation to duration of palsy before starting treatment shows that they were better in the earlier cases. Of the 66 patients who were treated in the first two days of paralysis 47 recovered completely, but 14 receiving corticotrophin developed denervation compared with five on prednisolone (x2 = 4 73, n = 1, 0-025 <P <0 05). Ofthe 120who were first treated on the third or fourth day of palsy 94 recovered completely, while 18 on corticotrophin and 8 on prednisolone developed denervation (x2 = 3-60, n = 1, 0 05 <P <0-1).
The mean percentage recovery in all the patients on corticotrophin was assessed at 70% and in the prednisolone patients it was 78%. The difference is not statistically significant, but the visual assessment of percentage recovery is crude and unreliable. However, severe denervation with less than 50% recovery of function is more reliably assessed (Table II) . It was found in 6 of the 94 patients on corticotrophin and in none of the 92 on prednisolone (d = 2-38, 0-01 <P <0 02).
Side effects of indigestion and transient oedema were encountered in seven patients, but did not interrupt treatment.
One patient developed severe haematemesis needing inpatient therapy and had to be withdrawn from the trial. In retrospect it was clear that he should not have been admitted to the trial because he had a history of peptic ulceration.
Discussion
Controlled trials of treatment in Bell's palsy are difficult to perform because of delay in starting therapy which is likely to prejudice the result. For this reason the patients were subdivided into early and late groups. Sixty-six started treatment on the first or second day of paralysis and 120 on the third or fourth days. The results of earlier treatment were indeed better, though both groups showed benefit. However, in very severe attacks the major damage may be done within the first few hours and treatment should be started at once.
It has previously been shown that the outcome in untreated Bell's palsy becomes worse with increasing age (Langworth and Taverner, 1963) so the patients were further subdivided into young and older groups. There were 104 patients in the young group and 82 in the older group. The expected difference was observed, but in the whole series the mean age of the patients who developed denervation was 44-6 years for the corticotrophin group and 43 9 years for the prednisolone group.
Assessment of the result of treatment is a difficult problem even if very elaborate methods are used. The presence or absence of denervation can be determined by the appearance of associated movements (Langworth and Taverner, 1963) , and this is the strictest criterion available. The results now reported are based almost entirely on this finding. We are well aware of the unreliability of subjective estimates of the difference in movement of the two sides of the face, but the statistically significant differences reported here are considerable and it is unlikely that observer error is responsible. The actual assessments of recovery in the severely denervated patients receiving corticotrophin mentioned above were 10%, 15%, 10%, 10%, 15%, and 15%, while all who took prednisolone were assessed at 50% recovery or above.
We had hoped to show that corticotrophin injections gave better results than oral prednisolone if only because a previous trial of cortisone for Bell's palsy gave a negative result (Tavemer, 1954) . In retrospect it is clear that the 1954 trial was intadequately planned to produce a reliable result. The treatment was started far too late to be effective, the dose of cortisone was too low, and the number of patients tested was too small.
At present we believe that oral prednisolone is the treatment of choice in Bell's palsy and should be given in full doses from the day of onset. The small risk of serious side effects is acceptable in view of the significant reduction in the incidence of severe denervation. Summary Thiopropazate (Dartalan) was found to be significantly more effective than a placebo in relieving dyskinesia in 23 patients with functional psychosis and persistent dyskinesia associated with prolonged phenothiazine therapy. Each patient whose dyskinesia had persisted unchanged for at least one month after phenothiazine withdrawal received thiopropazate by mouth for three weeks and the placebo for a similar period. Patients were evaluated before the trial, at three weeks, and at six weeks.
The drug also improved psychotic behaviour. Possible side effects, which were generally mild, were noted in eight patients, of whom six had Parkinsonism and four drowsiness. None had side effects while on the placebo.
The findings indicate that thiopropazate is of value in persistent dyskinesia associated with prolonged phenothiazine intake-a condition hitherto unresponsive to
Introduction
The treatment of persistent dyskinesia associated with prolonged phenothiazine therapy has been unsatisfactory. Brandrup (1961) reported success with tetrabenazine in four patients (but we could find no further report on the value of this drug) and Roxburgh (1970) used thiopropazate successfully in two patients. Thiopropazate hydrochloride (Dartalan) is chemically described as 10-(3[4-(2-acetyoxyethyl)piperazin-1-yl]propyl)-2-chlorophenothiazine dihydrochloride and is a phenothiazine structurally closely related to chlorpromazine. It has been reported to be of value in schizophrenia (Hamilton et al., 1960) . Reports on its effectiveness in controlling choreiform movements have been confined to Huntingdon's chorea (Mathews, 1958; Bruyn, 1962; Lyon, 1962) apart from, so far as we can trace, one case each of non-hereditary chorea (Lyon, 1962) , probable senile chorea with polycythaemia (Heathfield, 1968) , and Sydenham's chorea activated by oral contraceptives (Lewis and Harrison, 1969) . Kabat and McLeod (1959) reported improvement of involuntary movements in 24 cases of cerebellar ataxia and intention tremor.
Persistent dyskinesia affecting the face, mouth, tongue, and jaw (oral dyskinesia) is well known as an insidious and late
